These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 20570059)

  • 1. Retention in naltrexone implant treatment for opioid dependence.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Hegstad S; Gossop M; Kristensen O; Waal H
    Drug Alcohol Depend; 2010 Sep; 111(1-2):166-9. PubMed ID: 20570059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
    Fishman MJ; Winstanley EL; Curran E; Garrett S; Subramaniam G
    Addiction; 2010 Sep; 105(9):1669-76. PubMed ID: 20626723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
    Carreño JE; Alvarez CE; Narciso GI; Bascarán MT; Díaz M; Bobes J
    Addict Biol; 2003 Dec; 8(4):429-38. PubMed ID: 14690879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges to antagonist blockade during sustained-release naltrexone treatment.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Gossop M; Hegstad S; Kristensen Ø; Waal H
    Addiction; 2010 Sep; 105(9):1633-9. PubMed ID: 20707781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
    Waal H; Frogopsahl G; Olsen L; Christophersen AS; Mørland J
    Eur Addict Res; 2006; 12(3):138-44. PubMed ID: 16778434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
    Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD
    Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-acting naltrexone--a new way out of opiate addiction?].
    Stavseth LS; Kunøe N; Tanum L
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2231-2. PubMed ID: 24226324
    [No Abstract]   [Full Text] [Related]  

  • 10. [Alcohol consumption in opioid-dependence patients in treatment with naltrexone].
    Ochoa Mangado E; Arias Horcajadas F
    Actas Esp Psiquiatr; 2000; 28(4):239-49. PubMed ID: 11116795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
    Poser W; Ehrenreich H
    Internist (Berl); 1996 Oct; 37(10):1061-7; discussion 1067. PubMed ID: 9019453
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.
    Hulse GK; Ngo HT; Tait RJ
    Biol Psychiatry; 2010 Aug; 68(3):296-302. PubMed ID: 20537615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.
    Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson R; O'Neil P
    Addict Biol; 2004 Mar; 9(1):59-65. PubMed ID: 15203440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of information in naltrexone study.
    Rastegar DA
    Arch Gen Psychiatry; 2007 Jul; 64(7):865; author reply 865. PubMed ID: 17606820
    [No Abstract]   [Full Text] [Related]  

  • 16. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
    Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
    Fishman M
    Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.